Exploration of Piperidinols as Potential Antitubercular Agents

Novel drugs to treat tuberculosis are required and the identification of potential targets is important. Piperidinols have been identified as potential antimycobacterial agents (MIC < 5 μg/mL), which also inhibit mycobacterial arylamine N-acetyltransferase (NAT), an enzyme essential for mycobacterial survival inside macrophages. The NAT inhibition involves a prodrug-like mechanism in which activation leads to the formation of bioactive phenyl vinyl ketone (PVK). The PVK fragment selectively forms an adduct with the cysteine residue in the active site. Time dependent inhibition of the NAT enzyme from Mycobacterium marinum (M. marinum) demonstrates a covalent binding mechanism for all inhibitory piperidinol analogues. The structure activity relationship highlights the importance of halide substitution on the piperidinol benzene ring. The structures of the NAT enzymes from M. marinum and M. tuberculosis, although 74% identical, have different residues in their active site clefts and allow the effects of amino acid substitutions to be assessed in understanding inhibitory potency. In addition, we have used the piperidinol 3-dimensional shape and electrostatic properties to identify two additional distinct chemical scaffolds as inhibitors of NAT. While one of the scaffolds has anti-tubercular activity, both inhibit NAT but through a non-covalent mechanism.

[1]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[2]  E. Garman,et al.  Structure of arylamine N-acetyltransferase from Mycobacterium tuberculosis determined by cross-seeding with the homologous protein from M. marinum: triumph over adversity. , 2013, Acta crystallographica. Section D, Biological crystallography.

[3]  Randy Osborne,et al.  First novel anti-tuberculosis drug in 40 years , 2013, Nature Biotechnology.

[4]  A. Abuhammad Arylamine N-Acetyltransferases from mycobacteria : investigations of a potential target for anti-tubercular therapy , 2013 .

[5]  E. Garman,et al.  Piperidinols That Show Anti-Tubercular Activity as Inhibitors of Arylamine N-Acetyltransferase: An Essential Enzyme for Mycobacterial Survival Inside Macrophages , 2012, PloS one.

[6]  Charlotte M. Deane,et al.  Freely Available Conformer Generation Methods: How Good Are They? , 2012, J. Chem. Inf. Model..

[7]  Ulf R Dahle [Totally drug resistant tuberculosis?]. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[8]  Camilla Rodrigues,et al.  Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  K. Rowland Totally drug-resistant TB emerges in India , 2012, Nature.

[10]  Ximing Xu,et al.  The Bacillus anthracis arylamine N‐acetyltransferase ((BACAN)NAT1) that inactivates sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes , 2011, FEBS letters.

[11]  D. Staunton,et al.  Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents. , 2011, Protein expression and purification.

[12]  Takushi Kaneko,et al.  Challenges and opportunities in developing novel drugs for TB. , 2011, Future medicinal chemistry.

[13]  W. Graham Richards,et al.  Improving the accuracy of ultrafast ligand-based screening: incorporating lipophilicity into ElectroShape as an extra dimension , 2011, J. Comput. Aided Mol. Des..

[14]  M. Suresh,et al.  An overview of tuberculosis chemotherapy - a literature review. , 2011, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[15]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[16]  A. Russell,et al.  Novel small-molecule inhibitors of arylamine N-acetyltransferases: drug discovery by high-throughput screening. , 2011, Combinatorial chemistry & high throughput screening.

[17]  Raman Sharma,et al.  ElectroShape: fast molecular similarity calculations incorporating shape, chirality and electrostatics , 2010, J. Comput. Aided Mol. Des..

[18]  C. Dye,et al.  The Population Dynamics and Control of Tuberculosis , 2010, Science.

[19]  M. Noble,et al.  Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site , 2010, Protein & Cell.

[20]  G. Besra,et al.  Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars , 2010, Protein & Cell.

[21]  S. Bhakta,et al.  Rapid methods for testing inhibitors of mycobacterial growth. , 2010, Methods in molecular biology.

[22]  Pedro J Ballester,et al.  Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases , 2010, Journal of The Royal Society Interface.

[23]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[24]  Garrett M. Morris,et al.  Molecular similarity including chirality. , 2009, Journal of molecular graphics & modelling.

[25]  E. Sim,et al.  Comparison of the Arylamine N-Acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis , 2009, The protein journal.

[26]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[27]  G. Friedland,et al.  Extensively drug-resistant tuberculosis: a new face to an old pathogen. , 2009, Annual review of medicine.

[28]  W. Jacobs,et al.  Studies of a Ring-Cleaving Dioxygenase Illuminate the Role of Cholesterol Metabolism in the Pathogenesis of Mycobacterium tuberculosis , 2009, PLoS pathogens.

[29]  James Robinson,et al.  Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. , 2009, Bioorganic & medicinal chemistry.

[30]  M. Noble,et al.  Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. , 2008, Journal of molecular biology.

[31]  H. Gul,et al.  Evaluation of Anticonvulsant Activities of Bis(3-aryl-3-oxo-propyl)ethylamine Hydrochlorides and 4-Aryl-3-arylcarbo-nyl-1-ethyl-4-piperidinol Hydrochlorides , 2007, Arzneimittelforschung.

[32]  G. Besra,et al.  Characterization of the putative operon containing arylamine N‐acetyltransferase (nat) in Mycobacterium bovis BCG , 2006, Molecular microbiology.

[33]  F. Şahin,et al.  Evaluation of Antimicrobial Activities of Several Mannich Bases and Their Derivatives , 2005, Archiv der Pharmazie.

[34]  M. Milburn,et al.  The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Wagner,et al.  Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. , 2005, Biochemical pharmacology.

[36]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[37]  A. Ćwik,et al.  An efficient and environmental-friendly synthesis of 4-hydroxy-arylpiperidines using hydrotalcite catalyst , 2004 .

[38]  S. Gordon,et al.  Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target , 2004, The Journal of experimental medicine.

[39]  H. Gul,et al.  Anti-inflammatory activity of 3-benzoyl-1-methyl-4-phenyl-4-piperidinol hydrochloride. , 2003, Pharmacological research.

[40]  F. Pompeo,et al.  An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. , 2003, Bioorganic & medicinal chemistry.

[41]  E. De Clercq,et al.  Cytotoxic and anticancer properties of some 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinols and related compounds. , 2001, Die Pharmazie.

[42]  M. Noble,et al.  Structure of arylamine N-acetyltransferase reveals a catalytic triad , 2000, Nature Structural Biology.

[43]  E. Sim,et al.  Cloning and Characterization of Arylamine N -Acetyltransferase Genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased Expression Results in Isoniazid Resistance , 1999, Journal of bacteriology.

[44]  Robert H. Gilman,et al.  Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay , 1998, Journal of Clinical Microbiology.

[45]  B. Gee,et al.  Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis , 1995, Journal of clinical microbiology.

[46]  K. Sloan,et al.  Mannich base derivatives of theophylline and 5-fluorouracil: syntheses, properties and topical delivery characteristics , 1984 .

[47]  R. Kitz,et al.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.

[48]  E. Jeney,et al.  [Studies in search of new tuberculostatic drugs. I. Hydrazine derivatives, carbolic acid, phenols, quaternary ammonium compounds and their intermediaries]. , 1956, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale.

[49]  K. Shadan,et al.  Available online: , 2012 .